CyberKnife Market Size, Share & Trends Analysis Report By Application (Tumor, Cancer, Vascular Malformation), By End-use (Hospitals, Outpatient Facilities, Research & Manufacturing), By Region, And Segment Forecasts, 2025 - 2030

CyberKnife Market Size & Trends

The global cyberknife market size was estimated at USD 637.4 million in 2024 and is projected to grow at a CAGR of 17.6% from 2025 to 2030. The increasing prevalence of cancer, recent product launches, and growing preference for non-invasive or minimally invasive procedures over surgery are the factors propelling the growth of the industry. The increasing prevalence of cancer is the most prominent factor driving the market growth. Factors contributing to the rise of the prevalence of cancer include increasing tobacco use, rising alcohol consumption, lack of physical activity, and growing adoption of unhealthy diets by individuals.

A 2024 CDC study highlights that nearly 90% of lung cancer fatalities are attributable to smoking or exposure to secondhand smoke. This underscores that tobacco consumption significantly elevates cancer risk. Consequently, a growing smoking population correlates with an increased number of individuals at risk of developing lung cancer, emphasizing the urgent need for targeted public health interventions.

New product launches by the key players are also substantially contributing to market growth. For instance, in August 2024, Apollo Cancer Centre Bengaluru launched South Asia’s first CyberKnife*S7 FIM Robotic Radio Surgery System in India. This next-generation platform offers non-invasive radiation therapy to effectively treat both cancerous and benign tumors throughout the body, enhancing the operational efficiency of clinicians.

Several factors, including reduced hospital stays, lower trauma, quicker recovery times, and cost-effectiveness compared to surgical procedures, encourage more patients to choose non-invasive or minimally invasive options. These procedures effectively target cancer cells, damaging their DNA and inhibiting spread. Consequently, ongoing technological advancements in cancer treatment are anticipated to drive market growth for these modalities.

Application Insights

Cancer led the market and accounted for a share of 43.8% in 2024. The American Cancer Society estimates that in 2023, approximately 1,958,310 new cancer cases will be diagnosed in the U.S., with the five most prevalent types being breast, prostate, lung, bronchial, and colorectal cancers. Furthermore, the increasing adoption of CyberKnife technology for treating various cancer types is contributing to significant growth in this market segment. This trend highlights the growing recognition of innovative treatment options in enhancing patient outcomes and advancing cancer care.

Vascular malformation is expected to grow at the fastest CAGR of 17.8% over the forecast period, owing to their effectiveness in managing arteriovenous malformations. This non-surgical, non-invasive procedure utilizes a precisely targeted beam of radiation to damage the blood vessel walls, effectively closing the AVM. These treatments are performed with exceptional accuracy by leveraging cutting-edge technology, underscoring their potential to enhance patient outcomes.

End-use Insights

The hospitals segment led the market and accounted for a share of 51.2% in 2024, fueled by highly skilled professionals and an increasing volume of patient visits. Moreover, the rise in the number of hospitals aimed at accommodating the growing patient demand further contributes to segment growth. These factors highlight the evolving healthcare landscape and the commitment to enhancing patient care through expanded resources and expertise.

Outpatient facilities are projected to grow at the fastest CAGR of 17.8% over the forecast period. Ambulatory surgical centers  and specialty clinics are anticipated to grow significantly during the forecast period. This growth is primarily attributed to advantages such as shorter waiting times and lower overall costs, including reduced out-of-pocket patient expenses. These factors enhance accessibility and affordability, positioning these facilities as increasingly attractive options for patients seeking efficient and cost-effective surgical care.

Regional Insights

North America cyberknife market dominated the global market with a revenue share of 41.5% in 2024. Factors such as the rising prevalence of chronic diseases, a significant shift towards painless and non-invasive surgical procedures, and increasing demand for efficient treatments are driving market growth in the region. According to the American Society for Radiation Oncology, the number of radiation facilities in the U.S. grew from 1,987 in 2005 to 2,332 in 2020, reflecting a 17.0% increase. Investments in healthcare infrastructure and favorable reimbursement policies further enhance patient access to innovative treatments.

U.S. CyberKnife Market Trends

The cyberknife market in the U.S. dominated the North America market with a revenue share of 84.6% in 2024, fueled by the high incidence of cancer cases, with approximately 1.96 million new diagnoses in 2023. Technological advancements in CyberKnife systems and a shift towards outpatient treatment options drive demand for these innovative therapies, providing patients greater accessibility and satisfaction.

Europe CyberKnife Market Trends

Europe cyberknife market held a substantial market share in 2024, driven by the rising cancer burden, with approximately 3.7 million new cases reported annually. Advanced radiation therapies, rising healthcare expenditures, and a growing preference for minimally invasive procedures among patients and healthcare providers contribute to market growth.

The cyberknife market in Germany is expected to grow lucratively in the forecast period, aided by its aging population, with approximately 22% of citizens aged 65 and older. The high prevalence of chronic diseases, including cancer, alongside advanced healthcare infrastructure and investment in cutting-edge technologies, drives the adoption of CyberKnife systems for effective treatment options.

Latin America CyberKnife Market Trends

Latin America cyberknife market is expected to register the fastest CAGR of 19.1% in the forecast period. The region is experiencing an increasing incidence of cancer, with projections indicating over 1 million new cases annually. Enhanced government initiatives to improve healthcare access and affordability and growing awareness of advanced treatment options among patients contribute to the market’s growth.

The cyberknife market in Brazil dominated the Latin America cyberknife market in 2024, supported by a growing population of over 213 million people. The number of cancer cases is expected to rise to 600,000 annually by 2025. Investments in healthcare infrastructure and advancements in medical technology promote the adoption of innovative treatments such as CyberKnife for effective cancer management.

Key CyberKnife Company Insights

Some key companies operating in the market include Microsoft Corporation, IBM Corporation, Amazon.com, Inc., and Google LLC (Alphabet Inc.). In an attempt to establish a strong position in the market, key players are carrying out various strategic initiatives such as mergers and acquisitions, partnerships, collaboration, and expansion. These strategies help companies expand the reach of their products and enhance the overall quality of their products with additional expertise.

• Accuray is a leading entity in the CyberKnife market, offering the CyberKnife® S7 system for precise stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). It leverages advanced technologies to improve patient outcomes and optimize clinical workflows.

• Koninklijke Philips contributes to the CyberKnife market by providing advanced imaging and diagnostic technologies that enhance radiation therapy. While not a primary manufacturer of CyberKnife systems, Philips’ solutions support precise tumor targeting during radiosurgery procedures.

Recent Developments

• In January 2025, Accuray Incorporated announced the approval of the Radixact SynC and CyberKnife S7 Systems by China’s National Medical Products Administration, enhancing its radiation therapy portfolio in the region.

• In June 2024, Heidelberg University Hospital in Germany invested in the Radixact System, enhancing cancer patient care with advanced radiation therapy technology from Accuray Incorporated.

• In September 2023, Kenyatta University Teaching, Referral, and Research Hospital in Kenya commissioned the first CyberKnife radiotherapy system in Sub-Saharan Africa, advancing access to high-precision cancer treatment.

CyberKnife Market Report Scope

Global CyberKnife Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global cyberknife market report based on application, end-use, and region:

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Tumor

  • Cancer

  • Vascular Malformation

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Outpatient Facilities

  • Research & Manufacturing

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait